학술논문
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
Document Type
Article
Author
Source
In Blood Advances 27 February 2024 8(4):867-877
Subject
Language
ISSN
2473-9529